About

Publications While At HealthPartners

selected publications

Journal Article

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 

Lancet Oncology. 2018

Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. 

New England Journal of Medicine. 2017

Contact

full name

K Zylla DMKubiak

Quick Info

 

Collaboration

Co-author network

Map of science